Literature DB >> 18300421

Investigation of the angiogenic programme with tissue-specific and inducible genetic approaches in mice.

Ralf H Adams1.   

Abstract

Blood vessels form a highly organized hierarchical network throughout the vertebrate body, integrate functionally into very different tissue environments and remain remarkably adaptable to changing local requirements. The importance of a correctly formed and functional vascular network is highlighted by numerous human pathologies, which involve defects such as compromised blood circulation, destabilization of vessel walls or deregulated angiogenesis. Genetically modified mice are powerful tools for the functional characterization of genes, and can also serve as models of human diseases. However, targeted inactivation of genes essential for blood vessel morphogenesis is usually incompatible with embryonic survival, so studies in adult mice are precluded. Moreover, mutant phenotypes can be a complex combination of defects in different tissues and cell types. Tissue-specific and inducible genetic approaches allow us to overcome many of these limitations. In particular, it is possible to perform manipulations in a spatially (i.e. cell type-specific) and temporally controlled fashion, which makes possible studies throughout development and in adults. We have generated several transgenic Cre and tamoxifen-induble CreERT2 lines that enable the selective targeting of vascular cell populations. Here, I will discuss the characterization of these lines and present examples of their application in the analysis of vascular development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18300421     DOI: 10.1002/9780470319413.ch13

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  1 in total

1.  Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Authors:  Kyriakos P Papadopoulos; Eytan Ben-Ami; Amita Patnaik; Denise Trone; Jianke Li; George D Demetri
Journal:  BMC Cancer       Date:  2018-08-06       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.